IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Takeda was the world’s num ber 16 phar ma ceu ti cal cor po rate group and Ja pan’s lead ing phar ma ceu ti -
cal cor po ra tion in the year end ing Sep tem ber 2008, ac cord ing to IMS. Un til re cent years, Takeda was
by far the larg est Jap a nese pharmaceuticals com pany, but a wave of con sol i da tion ac tiv ity in the Jap a -
nese in dus try has pro duced com pa nies with a bulk that has at points chal lenged Takeda’s dom i nance.
Takeda has for many years been heavily re li ant on sales from four global stra te gic prod ucts: Actos
(pioglitazone) for type 2 di a be tes; the antiulcerant Takepron/Prevacid (lansoprazole); Blopress
(candesartan) for hy per ten sion and Lupron/Leuplin (leuprorelin) for pros tate can cer. The main chal lenge
for Takeda has been pro duc ing strong pipe line can di dates that will plug the gap as all four prod ucts lose
pat ent pro tec tion over the next five years, some thing that Takeda has ad dressed pri mar ily through li -
cens ing deals and ac qui si tions. In May 2008, Takeda com pleted the larg est ever ac qui si tion by a Jap a -
nese com pany, of US on col ogy com pany Mil len nium Pharma in a Yen1 tril lion deal, boost ing its on col ogy
pipe line and over seas pres ence. Takeda has made a num ber of ac qui si tions over re cent years to boost its
pipe line, in clud ing that of Paridigm Ther a peu tics, Syrrx and Amgen Ja pan which in cluded the in au gu ra -
tion of most of Amgen Ja pan’s (mainly on col ogy) pipe line. Takeda has a strong over seas pres ence and
has had a long-stand ing and very suc cess ful joint ven ture (TAP Pharmaceuticals) in the US mar ket with
Abbott, but the loss of ex clu siv ity for TAP’s main prod uct, Takepron/Prevacid re sulted in a de clin ing con -
tri bu tion from TAP. Af ter 30 years to gether, Takeda de cided to dis solve the jv from mid-2008 and has
bought Abbott’s share, gain ing full rights to Takepron in re turn for Lupron. Takeda’s fol low-on prod ucts
for Takepron and Actos, Kapidex (TAK 390MR) and alogliptin (SYR 322), have suf fered ag o niz ing de lays
in FDA re view for ap proval dates but are near ing the mar ket and Takeda hopes that their launch along
with growing sales of Millennium’s anticancer drug Velcade (bortezomib) to start bridging the gap as the
patents losses are realized.
Share Data: Shares are quoted on the Lon don, Osaka, To kyo, Nagoya, Fukuoka, Hi ro shima, Sapporo
and Niigata Stock Ex changes.
Takeda has the fol low ing busi ness seg ments:
� Pharmaceuticals (in clud ing ethicals and con sumer healthcare)
��Other Prod ucts (in clud ing food, chem i cals, an i mal health)
© 2009 IMS Health In cor po rated or its af fil i ates Page 6